Stock Track | Day One Biopharmaceuticals Plunges 11.34% After-Hours Despite Beating EPS Estimates

Stock Track

Aug 06, 2025

Shares of Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) tumbled 11.34% in after-hours trading on Tuesday, despite the company reporting better-than-expected earnings per share for the second quarter of 2025. The sharp decline highlights investors' concerns over missed revenue targets and ongoing net losses.

Day One reported a quarterly loss of $(0.29) per share, surpassing analyst expectations of $(0.35) by 17.14%. However, this still represents a significant increase in losses compared to the same period last year when the company reported a loss of $(0.05) per share. More importantly, the biopharmaceutical firm's quarterly sales of $33.908 million fell short of the analyst consensus estimate of $35.926 million by 5.62%, despite showing a substantial year-over-year increase of 313.92%.

The company's net income for the quarter remained negative at $30.322 million, raising concerns about its path to profitability. While Day One provided guidance for its flagship product Ojemda, projecting full-year 2025 net product revenue between $140 to $150 million, it seems the market was looking for stronger overall performance and a clearer route to positive earnings. The after-hours plunge suggests that investors are reassessing the company's growth trajectory and financial health in light of these mixed results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1109012498"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109012498\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1109012498?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 04:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109012498","market":"sg","top_or_hot":-1,"title":"Stock Track | Day One Biopharmaceuticals Plunges 11.34% After-Hours Despite Beating EPS Estimates","media":"Stock Track","content":"<p>Shares of Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) tumbled 11.34% in after-hours trading on Tuesday, despite the company reporting better-than-expected earnings per share for the second quarter of 2025. The sharp decline highlights investors' concerns over missed revenue targets and ongoing net losses.</p>\n\n<p>Day One reported a quarterly loss of $(0.29) per share, surpassing analyst expectations of $(0.35) by 17.14%. However, this still represents a significant increase in losses compared to the same period last year when the company reported a loss of $(0.05) per share. More importantly, the biopharmaceutical firm's quarterly sales of $33.908 million fell short of the analyst consensus estimate of $35.926 million by 5.62%, despite showing a substantial year-over-year increase of 313.92%.</p>\n\n<p>The company's net income for the quarter remained negative at $30.322 million, raising concerns about its path to profitability. While Day One provided guidance for its flagship product Ojemda, projecting full-year 2025 net product revenue between $140 to $150 million, it seems the market was looking for stronger overall performance and a clearer route to positive earnings. The after-hours plunge suggests that investors are reassessing the company's growth trajectory and financial health in light of these mixed results.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Day One Biopharmaceuticals Plunges 11.34% After-Hours Despite Beating EPS Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Day One Biopharmaceuticals Plunges 11.34% After-Hours Despite Beating EPS Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-06 04:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) tumbled 11.34% in after-hours trading on Tuesday, despite the company reporting better-than-expected earnings per share for the second quarter of 2025. The sharp decline highlights investors' concerns over missed revenue targets and ongoing net losses.</p>\n\n<p>Day One reported a quarterly loss of $(0.29) per share, surpassing analyst expectations of $(0.35) by 17.14%. However, this still represents a significant increase in losses compared to the same period last year when the company reported a loss of $(0.05) per share. More importantly, the biopharmaceutical firm's quarterly sales of $33.908 million fell short of the analyst consensus estimate of $35.926 million by 5.62%, despite showing a substantial year-over-year increase of 313.92%.</p>\n\n<p>The company's net income for the quarter remained negative at $30.322 million, raising concerns about its path to profitability. While Day One provided guidance for its flagship product Ojemda, projecting full-year 2025 net product revenue between $140 to $150 million, it seems the market was looking for stronger overall performance and a clearer route to positive earnings. The after-hours plunge suggests that investors are reassessing the company's growth trajectory and financial health in light of these mixed results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DAWN","symbol_name":"Day One Biopharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1109012498","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109012498","pubTimestamp":1754426016,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) tumbled 11.34% in after-hours trading on Tuesday, despite the company reporting better-than-expected earnings per share for the second quarter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DAWN":"Day One Biopharmaceuticals Inc."},"translate_title":"个股追踪|Day One生物制药盘后暴跌11.34%尽管EPS超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DAWN":1},"content_text":"Shares of Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) tumbled 11.34% in after-hours trading on Tuesday, despite the company reporting better-than-expected earnings per share for the second quarter of 2025. The sharp decline highlights investors' concerns over missed revenue targets and ongoing net losses.\nDay One reported a quarterly loss of $(0.29) per share, surpassing analyst expectations of $(0.35) by 17.14%. However, this still represents a significant increase in losses compared to the same period last year when the company reported a loss of $(0.05) per share. More importantly, the biopharmaceutical firm's quarterly sales of $33.908 million fell short of the analyst consensus estimate of $35.926 million by 5.62%, despite showing a substantial year-over-year increase of 313.92%.\nThe company's net income for the quarter remained negative at $30.322 million, raising concerns about its path to profitability. While Day One provided guidance for its flagship product Ojemda, projecting full-year 2025 net product revenue between $140 to $150 million, it seems the market was looking for stronger overall performance and a clearer route to positive earnings. The after-hours plunge suggests that investors are reassessing the company's growth trajectory and financial health in light of these mixed results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}